Scarica l'app Stockscreener
1.89
4.42%
0.08
Dopo l'orario di chiusura:
1.90
0.01
+0.53%
Precedente Chiudi:
$1.81
Aprire:
$1.82
Volume 24 ore:
379.25K
Relative Volume:
0.64
Capitalizzazione di mercato:
$98.87M
Reddito:
$21.05M
Utile/perdita netta:
$-89.22M
Rapporto P/E:
-1.0559
EPS:
-1.79
Flusso di cassa netto:
$-64.50M
1 W Prestazione:
+2.72%
1M Prestazione:
+22.73%
6M Prestazione:
-21.25%
1 anno Prestazione:
-74.29%
Intervallo 1D:
$1.80
$1.9399
Intervallo di 1 settimana:
$1.75
$1.9399
Portata 52W:
$1.02
$7.6399
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Nome
Tscan Therapeutics Inc
Settore
Industria
Telefono
857-399-9500
Indirizzo
880 WINTER STREET, WALTHAM
Confronta TCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.89 | 104.13M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-16 | Iniziato | BTIG Research | Buy |
| 2024-05-13 | Iniziato | Needham | Buy |
| 2023-06-22 | Iniziato | Wedbush | Outperform |
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
What makes TScan Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - Newser
Why TScan Therapeutics Inc. stock attracts strong analyst attentionFree Popular Stock Recommendations - Newser
How TScan Therapeutics Inc. stock performs during market volatility2x 3x 5x Pick Alert - Newser
TScan Therapeutics (NASDAQ:TCRX) Rating Increased to Hold at Wall Street Zen - Defense World
Great week for TScan Therapeutics, Inc. (NASDAQ:TCRX) institutional investors after losing 73% over the previous year - simplywall.st
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
TScan Therapeutics (NASDAQ:TCRX) Stock Price Down 4% – Time to Sell? - Defense World
TScan Therapeutics Elects New Directors at Annual Meeting - TipRanks
TScan Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from Russell 2000 Index - MarketScreener
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80 - Defense World
Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell - Defense World
Bank of America Corp DE Has $456,000 Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Wellington Management Group LLP Boosts Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
ProShare Advisors LLC Makes New $40,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BNP Paribas Financial Markets Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewswire
Cancer Therapy Pioneer TScan Therapeutics Set for Major Presentation at Jefferies Healthcare Conference - Stock Titan
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
New Data and Deal Flow Signal a Turning Point for Precision-Driv - GuruFocus
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Comparing TScan Therapeutics (NASDAQ:TCRX) and Twist Bioscience (NASDAQ:TWST) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Dimensional Fund Advisors LP Increases Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Stifel Financial Corp Acquires 10,567 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Barclays PLC - Defense World
H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating - Investing.com Nigeria
Equities Analysts Set Expectations for TCRX Q2 Earnings - Defense World
Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World
Wedbush Research Analysts Reduce Earnings Estimates for TCRX - Defense World
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $10.00 - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Position Trimmed by Renaissance Technologies LLC - Defense World
Brokers Offer Predictions for TCRX Q1 Earnings - Defense World
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
TScan Therapeutics (TCRX) Price Target Lowered by HC Wainwright | TCRX Stock News - GuruFocus
What Analysts Are Saying About TScan Therapeutics Stock - Benzinga
TScan Therapeutics Reports Q1 2025 Financial Results - TipRanks
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics (TCRX) Exceeds Q1 Revenue Expectations | TCRX Stock News - GuruFocus
TScan Therapeutics Reveals Solid Progress: Key Clinical Data Coming in 2025, $251M War Chest Secured - Stock Titan
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average Target Price from Brokerages - Defense World
JPMorgan Chase & Co. Acquires 34,951 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BlackRock, Inc. Reduces Stake in TScan Therapeutics Inc by 43.05% - GuruFocus
Tscan Therapeutics Inc Azioni (TCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):